FDA to expedite review of Lilly's gastric cancer drug

10/25/2013 | Pharmaceutical Business Review Online

The FDA granted priority-review designation to Eli Lilly & Co.'s biologics license application for ramucirumab, or IMC-1121B, for treatment of patients with advanced gastric cancer whose disease progressed after initial chemotherapy. The drug is also under regulatory review in Europe.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC